RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $61
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $53 to $61.
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $53 to $61.